< Back to Longitude Capital News

Aviceda Therapeutics is a biotechnology company developing next-generation immunomodulators with a proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform to alleviate chronic, non-resolving inflammation.